Hemab Therapeutics Holdings, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Use of Proceeds from IPO
On May 4, 2026, we closed our IPO, pursuant to which we issued and sold 19,262,500 shares of our common stock, including 2,512,500 shares sold by us pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $18.00 per share for aggregate gross proceeds of approximately $346.7 million. We received aggregate net proceeds from the IPO of approximately $317.2 million, after deducting underwriting discounts and commissions and other offering expenses of $29.6 million payable by us. There has been no material change in our planned use of proceeds from the IPO as described in the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on May 1, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.